Please ensure Javascript is enabled for purposes of website accessibility

Why Amicus Therapeutics Stock Is Soaring Today

By Keith Speights - Apr 14, 2021 at 12:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered an analyst's upgrade of the biotech stock.

What happened

Shares of Amicus Therapeutics (FOLD 0.56%) were soaring 9.7% higher at 12:07 p.m. EDT on Wednesday. The big gain came after Cantor Fitzgerald analyst Kristen Kluska upgraded Amicus stock to overweight from neutral.

So what

It's best to take analysts' ratings with a grain of salt. However, understanding the reason behind their optimism about a given stock can be helpful.

In this case, Cantor Fitzgerald's Kluska likes the prospects for Amicus because she thinks the company's gene therapy candidates are promising based on recent clinical updates. That's a pretty good reason to upgrade the biotech stock.

Two scientists looking through microscopes

Image source: Getty Images.

At a major clinical meeting earlier this year, Amicus presented positive results from its late-stage study evaluating AT-GAA in treating Pompe disease, a genetic disorder that causes sugar to build up in the body and damage muscles and organs. At the same meeting, it also reported good initial results from a phase 1/2 study of its CLN3 gene therapy in treating Batten disease, a neurological disorder that primarily affects children.

Now what

Amicus Therapeutics plans to submit for U.S. regulatory approval of AT-GAA in the second quarter of this year. The company expects to file for regulatory approval of the experimental drug in the European Union and other countries later in 2021. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amicus Therapeutics, Inc. Stock Quote
Amicus Therapeutics, Inc.
$10.80 (0.56%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.